AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8585775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1974143 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol LA (160 mg)
Number of subjects: 12
Study 1974143 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study 1974143 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR (100 mg)
Number of subjects: 12
Study 1974143 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockers (Propranolol LA, Atenolol, Metoprolol CR)
Number of subjects: 12
Study 1974143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 875101 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 58
Study 875101 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive steroids
Number of subjects: 58
Study 875101 — intervention group
Group type: COMPARATOR
Intervention: Increased fluid intake
Number of subjects: 58
Study 875101 — intervention group
Group type: COMPARATOR
Intervention: Increased glucose intake
Number of subjects: 58
Study 875101 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 58
Study 30470804 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) at 4200 kJ/day for women and 5040 kJ/day for men
Number of subjects: 332
Study 30470804 — intervention group
Group type: EXPERIMENTAL
Intervention: Week-on-week-off energy restriction (alternating between energy restriction and habitual diet)
Number of subjects: 332
Study 30470804 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:2 energy restriction (2100 kJ/day for women and 2520 kJ/day for men on modified fast days)
Number of subjects: 332
Study 30470804 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 332
Study 30361080 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (25 mg once nightly for the first 2 weeks, then 50 mg thereafter)
Number of subjects: 107
Study 30361080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 30361080 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 107
Study 26852237 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 750
Study 26852237 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Number of subjects: 750
Study 26852237 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 750
Study 23925496 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group-discussion (SGD) programme
Number of subjects: 2169
Study 23925496 — intervention group
Group type: COMPARATOR
Intervention: Practice-while-watching (PWW) programme
Number of subjects: 2169
Study 22965294 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) - Sensor On
Number of subjects: 153
Study 22965294 — intervention group
Group type: COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM) - Sensor Off
Number of subjects: 153
Study 20124412 — intervention group
Group type: COMPARATOR
Intervention: 75 mg of prednisolone (single dose)
Number of subjects: 29
Study 20124412 — intervention group
Group type: COMPARATOR
Intervention: 30 mg of prednisolone daily for 15 days
Number of subjects: 29
Study 20124412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 17535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic‐haptic (T‐T) discrimination
Number of subjects: 0
Study 17535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic‐visual (T‐V) discrimination
Number of subjects: 0
Study 17535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual‐visual (V‐V) discrimination
Number of subjects: 0
Study 17535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual‐haptic (V‐T) discrimination
Number of subjects: 0
Study 17535462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of inter‐modal (V‐T, T‐V) and intra‐modal (V‐V, T‐T) conditions
Number of subjects: 0
Study 16003198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable polylevolactic acid screw
Number of subjects: 38
Study 16003198 — intervention group
Group type: COMPARATOR
Intervention: Metallic screw
Number of subjects: 38
Study 16003198 — intervention group
Group type: EXPERIMENTAL
Intervention: Both screws
Number of subjects: 38
Study 12452207 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 331
Study 12452207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 10080158 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha (6 million units once a day for one month and thrice weekly for five months)
Number of subjects: 120
Study 10080158 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta (6 million units once a day daily for two months)
Number of subjects: 120
Study 10080158 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta (3 million units twice a day for two months)
Number of subjects: 120
Study 10080158 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 7555487 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1.0 mg)
Number of subjects: 8
Study 7555487 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Atropine
Number of subjects: 8
Study 7555487 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 8
Study 1970284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid enemas (4 gm daily for the first seven days of each month)
Number of subjects: 60
Study 1970284 — intervention group
Group type: COMPARATOR
Intervention: Oral sulfasalazine (2 gm daily as oral tablets)
Number of subjects: 60
Study 6164465 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (45 Gy) + Bleomycin (15 mg doses, total 180 mg)
Number of subjects: 118
Study 6164465 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (45 Gy) + Placebo
Number of subjects: 118
Study 6164465 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (no radiotherapy or chemotherapy)
Number of subjects: 118
Study 31500661 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral networks strengthened with health information technology and peer support
Number of subjects: 0
Study 31500661 — intervention group
Group type: COMPARATOR
Intervention: Usual care for referrals
Number of subjects: 0
Study 29295592 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic voltammetric tongue
Number of subjects: 83
Study 29295592 — intervention group
Group type: COMPARATOR
Intervention: Routine analytical methods
Number of subjects: 83
Study 25897676 — intervention group
Group type: COMPARATOR
Intervention: selumetinib 75 mg p.o. bid
Number of subjects: 71
Study 25897676 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly
Number of subjects: 71
Study 25897676 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib plus temsirolimus
Number of subjects: 71
Study 23400744 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil 250 µM
Number of subjects: 20
Study 23400744 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 20
Study 23400744 — intervention group
Group type: COMPARATOR
Intervention: Treprostinil 2.5 µM
Number of subjects: 20
Study 23400744 — intervention group
Group type: COMPARATOR
Intervention: Treprostinil 25 µM
Number of subjects: 20
Study 21078303 — intervention group
Group type: EXPERIMENTAL
Intervention: Perimenopausal hormone therapy (HT)
Number of subjects: 34
Study 21078303 — intervention group
Group type: COMPARATOR
Intervention: Never users of hormone therapy (HT)
Number of subjects: 34
Study 19961458 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary system
Number of subjects: 20
Study 19961458 — intervention group
Group type: COMPARATOR
Intervention: Nitiflex files (control)
Number of subjects: 20
Study 17278974 — intervention group
Group type: EXPERIMENTAL
Intervention: Alagebrium (ALT-711; 210 mg twice a day for 8 weeks)
Number of subjects: 13
Study 15126734 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 22
Study 15126734 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate (A/C)
Number of subjects: 22
Study 15126734 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Clarithromycin and A/C)
Number of subjects: 22
Study 10570555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbinafine 1% cream twice daily for 1 week, followed by placebo cream for 5 weeks
Number of subjects: 217
Study 10570555 — intervention group
Group type: COMPARATOR
Intervention: Topical clotrimazole 1% cream twice daily for 4 weeks
Number of subjects: 217
Study 10570555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbinafine
Number of subjects: 217
Study 10570555 — intervention group
Group type: COMPARATOR
Intervention: Topical clotrimazole
Number of subjects: 217
Study 8728447 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 26-30 years
Number of subjects: 756
Study 8728447 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged > 30 years
Number of subjects: 756
Study 8728447 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with Quetelet's index > 25-30
Number of subjects: 756
Study 8728447 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with Quetelet's index > 30
Number of subjects: 756
Study 8728447 — intervention group
Group type: EXPERIMENTAL
Intervention: Parous women (1 birth)
Number of subjects: 756
Study 8728447 — intervention group
Group type: EXPERIMENTAL
Intervention: Parous women (2 or more births)
Number of subjects: 756
Study 2008069 — intervention group
Group type: EXPERIMENTAL
Intervention: Milieu Teaching
Number of subjects: 40
Study 2008069 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Training Program
Number of subjects: 40
Study 6981176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) therapy for treatment: 20 mg of TMP and 100 mg of SMZ per kg of body weight per day
Number of subjects: 0
Study 6981176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic therapy: 5.0 mg of TMP and 25 mg of SMZ per kg of body weight per day
Number of subjects: 0
Study 6981176 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured delivery of prophylactic TMP-SMZ
Number of subjects: 0
Study 6981176 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine isethionate
Number of subjects: 0
Study 30507267 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% carbohydrate plus electrolyte (CHO‐E) solution
Number of subjects: 18
Study 30507267 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte placebo
Number of subjects: 18
Study 28159814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 359
Study 24296423 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri combination (2×10 Colony Forming Units)
Number of subjects: 100
Study 24296423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24296423 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri combination
Number of subjects: 100
Study 22676424 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg orally for 6 days)
Number of subjects: 11
Study 19936616 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hypothalamic deep brain stimulation (DBS)
Number of subjects: 11
Study 19936616 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study 17509328 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (200 U)
Number of subjects: 34
Study 17509328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15703774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 58
Study 15703774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic stress test
Number of subjects: 58
Study 15703774 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting vascular resistance
Number of subjects: 58
Study 11836455 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for weight loss
Number of subjects: 585
Study 11836455 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight/sodium reduction
Number of subjects: 585
Study 11836455 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 585
Study 10627793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-50 mg/day flexible dose)
Number of subjects: 290
Study 10627793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 8533543 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 10
Study 8533543 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 10
Study 1959686 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-labelled-leucocyte imaging at 2-5 days post-surgery
Number of subjects: 20
Study 1959686 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-labelled-leucocyte imaging at 7-10 days post-surgery
Number of subjects: 20
Study 1959686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical features, leucocyte counts, and C-reactive protein measurements
Number of subjects: 20
Study 6367380 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antihypertensive therapy
Number of subjects: 0
Study 6367380 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine, dihydralazine, diazoxide
Number of subjects: 0
Study 31596866 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (Control Group)
Number of subjects: 101
Study 26995381 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective early aortic valve replacement (AVR)
Number of subjects: 0
Study 26995381 — intervention group
Group type: COMPARATOR
Intervention: Medical management with vigilant follow-up
Number of subjects: 0
Study 25425308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle-by-cycle (CxC) ERG
Number of subjects: 54
Study 25425308 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 30-Hz flicker ERG
Number of subjects: 54
Study 22115710 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of sirolimus (220, 440, 880, 1320, or 1760 μg)
Number of subjects: 50
Study 22115710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of sirolimus (44, 110, 176, 264, or 352 μg)
Number of subjects: 50
Study 21969992 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted maximum likelihood estimator of causal effects of multiple time point interventions
Number of subjects: 0
Study 21969992 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial estimate of the unknown factors of the G-computation formula
Number of subjects: 0
Study 21969992 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal fluctuation function
Number of subjects: 0
Study 21969992 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection among different targeted maximum likelihood estimators
Number of subjects: 0
Study 17210768 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r plus ranitidine
Number of subjects: 16
Study 17210768 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/r plus omeprazole
Number of subjects: 16
Study 17210768 — intervention group
Group type: COMPARATOR
Intervention: DRV/r alone
Number of subjects: 16
Study 17473394 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cognitive training program for memory and working memory (6 weeks duration)
Number of subjects: 42
Study 17473394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study 15037403 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a administration starting on stimulation day 6 (group 1)
Number of subjects: 109
Study 15037403 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a administration starting when the leading follicle reached a mean diameter of 14 mm (group 2)
Number of subjects: 109
Study 11860914 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate tablets (800 mg of calcium daily)
Number of subjects: 112
Study 11860914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 9229983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2,000,000 IU as a bolus + 500,000 JU/h until the end of the operation)
Number of subjects: 18
Study 9229983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of diastolic blood pressure
Number of subjects: 11299
Study 1432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling risk of cardiovascular mortality
Number of subjects: 11299
Study 1432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of adjusting for regression dilution
Number of subjects: 11299
Study 1432027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential strategy for determining antihypertensive intervention
Number of subjects: 11299
Study 6499663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral instructions alone or in combination with written information
Number of subjects: 158
Study 6499663 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reminder calendar
Number of subjects: 158
Study 6499663 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reminder package
Number of subjects: 158
Study 6499663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reminder aid with oral reinforcement
Number of subjects: 158
Study 6499663 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of motivation in patients
Number of subjects: 158
Study 30876946 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF monotherapy
Number of subjects: 192
Study 29854085 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol for 8 weeks
Number of subjects: 0
Study 29854085 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 26721327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (HepB) booster
Number of subjects: 2
Study 25492697 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus neural mobilisation
Number of subjects: 0
Study 25492697 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22583609 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management programs
Number of subjects: 75
Study 19283599 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional behavioral parent training program
Number of subjects: 120
Study 19283599 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced behavioral parent training program - STEPP
Number of subjects: 120
Study 19283599 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study 17526180 — intervention group
Group type: EXPERIMENTAL
Intervention: Jieyu Anshen Decoction combined with aripiprazole
Number of subjects: 100
Study 17526180 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole alone
Number of subjects: 100
Study 16212807 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12529740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus oral anticoagulants (group B)
Number of subjects: 52
Study 12529740 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (group A)
Number of subjects: 52
Study 9583863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf)
Number of subjects: 50
Study 9583863 — intervention group
Group type: COMPARATOR
Intervention: Microemulsion cyclosporine (Neoral)
Number of subjects: 50
Study 9583863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf) and Microemulsion cyclosporine (Neoral)
Number of subjects: 50
Study 8588538 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II below-knee compression stockings
Number of subjects: 188
Study 2799345 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate
Number of subjects: 22
Study 1090418 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (5 mg daily)
Number of subjects: 22
Study 1090418 — intervention group
Group type: COMPARATOR
Intervention: Chlorothiazide (500 mg daily)
Number of subjects: 22
Study 1090418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30973182 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 54
Study 30973182 — intervention group
Group type: COMPARATOR
Intervention: Coffee with milk
Number of subjects: 54
Study 30973182 — intervention group
Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 54
Study 27685010 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 24
Study 27685010 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise only (RE)
Number of subjects: 24
Study 27685010 — intervention group
Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 24
Study 25698298 — intervention group
Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT + Treatment as Usual (TAU)
Number of subjects: 94
Study 25698298 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 94
Study 25698298 — intervention group
Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT + TAU
Number of subjects: 94
Study 24238308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesna injection
Number of subjects: 101
Study 24238308 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 101
Study 22852055 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural orange juice enriched with 11.25 g of levan
Number of subjects: 48
Study 22852055 — intervention group
Group type: COMPARATOR
Intervention: Natural orange juice without levan
Number of subjects: 48
Study 19254123 — intervention group
Group type: COMPARATOR
Intervention: CPT plus ADM
Number of subjects: 18
Study 19254123 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT plus ADM and PRP
Number of subjects: 18
Study 17448057 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual displacement of the uterus (group MD)
Number of subjects: 90
Study 17448057 — intervention group
Group type: COMPARATOR
Intervention: 15 degrees left lateral table tilt (group LT)
Number of subjects: 90